Here's what Jim Cramer had to say about some of the stocks during the Mad Money Lightning Round:

Universal Display (OLED) : "I've been behind this one forever and it's not done going higher."

Lumber Liquidators (LL) : "I'd rather see that money in Home Depot (HD) ."

Acuity Brands (AYI) : "This is unexciting stock."

The Trade Desk (TTD) : "I think it's up too high. You're on your own."

Automatic Data Processing (ADP) : "I'd like you to ring the register on half of your position."

On Real Money, Cramer says the worldwide synchronized growth keeps taking people by surprise. Get more on his insights with a free trial subscription to Real Money.

Cramer and the AAP team review the oil rally and Saudi corruption probe, and the impact on their portfolio. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To read a full recap of this episode of "Mad Money," click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

More of What's Trending on TheStreet:

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

More from Jim Cramer

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Jim Cramer: Bank of America Expects 4% Economic Growth in Q2

Jim Cramer: Bank of America Expects 4% Economic Growth in Q2

Illinois Tool Works, Deutsche Bank, ForeScout: 'Mad Money' Lightning Round

Illinois Tool Works, Deutsche Bank, ForeScout: 'Mad Money' Lightning Round

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth